Despite China’s hopes of recovering and rebounding from an ongoing economic downturn and COVID-19 disruptions, sharply rising deaths and the lingering impact of the pandemic are continuing to cloud investment, bringing little relief to the biotech and pharma sector.
One executive at a Shanghai-based gene therapy firm told Scrip that investor sentiment remains chilly, despite clinical data for new drugs continuing to shine